Zymeworks (NASDAQ:ZYME – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday.
Zymeworks Stock Performance
Zymeworks stock opened at $14.36 on Friday. Zymeworks has a 12-month low of $9.03 and a 12-month high of $17.70. The firm has a market cap of $1.08 billion, a P/E ratio of -14.80 and a beta of 1.26.
Zymeworks (NASDAQ:ZYME – Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.55. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The company had revenue of $48.73 million for the quarter, compared to the consensus estimate of $13.66 million.
About Zymeworks
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
See Also
- Five stocks we like better than Zymeworks
- Why Are Stock Sectors Important to Successful Investing?
- 3 Energy Stocks to Gain Exposure to the Carbon Capture Boom
- The Most Important Warren Buffett Stock for Investors: His Own
- AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple
- How to trade using analyst ratings
- The Real Reason Ford Stock Is Rallying—Can It Keep Going?
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
